Tibotec and Bristol-Myers Team Up to Battle Hepatitis C | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

Waiver Improves Quick Hep C Test Accessibility

Back to News Homepage
Next

Initial Hep C Data on ACH-2928 Is Encouraging

Tibotec and Bristol-Myers Team Up to Battle Hepatitis C

The Editors at Hepatitis Central
December 7, 2011

Print this page

A collaboration between pharma giants Bristol-Myers Squibb and Tibotec has been established to investigate Daclatasvir plus TMC435 against Hepatitis C genotype 1.

Bristol-Myers inks research deal with Tibotec for Daclatasvir

PBR Staff Writer

Published 05 December 2011

Bristol-Myers Squibb Company has entered into a clinical collaboration agreement with Sweden-based Medivir’s development partner, Tibotec Pharmaceuticals for Phase II combination study in patients with chronic hepatitis C virus (HCV).

The collaboration is intended to evaluate the utility of Daclatasvir (BMS-790052), Bristol-Myers Squibb’s investigational NS5A replication complex inhibitor, along with Tibotec Pharmaceuticals’ NS3 protease inhibitor, TMC435, for the treatment of chronic hepatitis C.

Continue reading this entire article:
http://contractresearch.pharmaceutical-business-review.com/news/bristol-myers-inks-research-deal-with-tibotec-for-daclatasvir-051211

No Comments - be the first!
Share
Share
Previous

Waiver Improves Quick Hep C Test Accessibility

Back to News Homepage
Next

Initial Hep C Data on ACH-2928 Is Encouraging

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.